| Category | Summary |
|---|---|
| Disease identifiers / synonyms / inheritance | HLD7 is listed as **Hypomyelinating leukodystrophy 7** with **OMIM/MIM 607694**; it is also described within **4H leukodystrophy** and broader **POLR3-related leukodystrophy / POLR3-HLD** nomenclature. Core synonym expansion of 4H is hypomyelination, hypodontia, and hypogonadotropic hypogonadism. Inheritance is **autosomal recessive / biallelic**. Evidence note: multiple sources converge on HLD7 as the POLR3A-associated recessive 4H/POLR3-HLD entity. (pqac-00000004, pqac-00000006, pqac-00000007, pqac-00000008, pqac-00000011) |
| Causal gene | Primary causal gene for HLD7 is **POLR3A** (RNA polymerase III subunit A; gene OMIM *614258), encoding the largest/catalytic core Pol III subunit involved in transcription of small non-coding RNAs including tRNAs and 5S rRNA. Related POLR3-HLD genes mentioned across the disease spectrum include **POLR3B, POLR1C, POLR3K**, and newer POLR3-related causes such as **POLR3D**, but HLD7 specifically maps to **POLR3A**. Evidence note: human genetic and functional studies consistently support POLR3A as the HLD7 gene. (pqac-00000001, pqac-00000003, pqac-00000006, pqac-00000011, pqac-00000022) |
| Hallmark clinical features and MRI pattern | Hallmark neurologic features include **motor delay/decline, spasticity, ataxia, tremor, dystonia, dysarthria, cerebellar signs, cognitive impairment/regression**; extra-neurologic features include **hypodontia/dental anomalies (including dentin dysplasia), hypogonadotropic hypogonadism, short stature, ocular findings**. MRI pattern typically shows **diffuse hypomyelination** with relative preservation of early-myelinating structures such as the **optic radiations, ventrolateral thalamus, globus pallidus/dentate nucleus**, plus **cerebellar atrophy** and **thinning/atrophy of the corpus callosum**; newer 3T descriptions include the **closed eye sign** and myelin islets. Evidence note: the classic 4H triad remains diagnostically useful, but phenotype and MRI severity are variable and diffuse hypomyelination is not obligatory in every POLR3-related presentation. (pqac-00000002, pqac-00000005, pqac-00000007, pqac-00000008, pqac-00000011, pqac-00000021, pqac-00000022) |
| Example pathogenic variants | Representative **POLR3A** variants reported in HLD7/POLR3-HLD include **c.2300G>T (p.Cys767Phe)** in a homozygous family with functional impairment of Pol III transcription; **c.1771-6C>G** and **c.2611del (p.M871Cfs*8)** as compound heterozygous variants in a Chinese case; **c.661_662insCCT (p.P220_L221insS)** with **c.1770+5G>C** causing aberrant splicing and **p.(P591Vfs*28)**; and a novel missense **c.328A>G (p.Lys110Glu)** in severe POLR3-related leukodystrophy. Evidence note: reported variant classes include missense, frameshift, splice-region, and in-frame insertion variants, reinforcing allelic heterogeneity. (pqac-00000001, pqac-00000003, pqac-00000009, pqac-00000013, pqac-00000022) |
| Key recent advances (2023–2024) | Recent work refined disease biology and heterogeneity: a 2023 review summarized HLD molecular mechanisms and confirmed HLD7/POLR3A as part of the expanding hypomyelinating leukodystrophy landscape; a 2024 family study showed **p.Cys767Phe** impairs Pol III outputs and lowers **MBP** and **18S rRNA** expression; 2024 precision-medicine work proposed **single-cell omics and drug screening** for leukodystrophies; and a 2024 mouse study supported **tRNA reduction, innate immune/integrated stress responses, oligodendrocyte loss, neuron loss, and microglial activation** as candidate disease mechanisms in Polr3-related disease. Evidence note: the field is shifting from descriptive genetics toward mechanism-based stratification and therapy discovery, though disease-specific interventional trials for HLD7 were not identified in the provided evidence. (pqac-00000001, pqac-00000016, pqac-00000018, pqac-00000019, pqac-00000022) |
| Model systems / translational clues | Model systems include **mouse oligodendroglial FBD-102b cells** expressing HLD7-associated **POLR3A R140X**, where mutant protein localized to **lysosomes**, reduced **mTOR** signaling, and impaired oligodendroglial differentiation; **ibuprofen** partially ameliorated these cellular defects in vitro. In vivo, an earlier **Polr3a G672E mouse** failed to recapitulate major neurologic/myelin phenotypes, highlighting model limitations, whereas a newer **postnatal whole-body Polr3a mutant mouse** showed behavioral deficits, cerebral pathology, altered tRNA pools, oligodendrocyte/neuron loss, and microglial activation. Evidence note: model systems support oligodendrocyte maturation failure as a central mechanism, but phenotypic fidelity depends strongly on allele/model design. (pqac-00000006, pqac-00000019, pqac-00000022) |


*Table: This table condenses the key disease-level facts for Hypomyelinating Leukodystrophy 7, including identifiers, gene, phenotype, MRI, representative variants, and recent mechanistic/model advances. It is useful as a compact evidence-backed reference for building a disease knowledge base entry.*